研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K.	G to A hypermutation of hepatitis B virus.	Hepatology	41	626-33	2005
Tsuge M, Takaishi H, Hiraga N, Noguchi C, Oga H, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Chayama K, Tateno C, Yoshizato K.	Infection of human hepatocyte chimeric mouse with genetically engeneered hepatitis B virus.	Hepatology	42	1046-54	2005
Takahashi S, Chayama K.	Integration of hepatitis B virus DNA and hepatocellular carcinoma.	J Gastroenterol	20	1141-2	2005
Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Suzuki F, Kumada H, Chayama K.	Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif	AMAC	50	3867-74	2006
Utoh R, Chayama K, at al	Hepatitis B Virus-Infectibility of Chimeric Mice with Liver Repopulated by Serially Subcultured Human Hepatocytes	Hepatology			In press
Uka K, Chayama K, at al	Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma	J Gastroenterol	42	845-853	2007
Yatsuji H, Chayama K, at al	Successful treatment of an entecavir-resistant hepatitis B virus variant	J Med Virol	79	1811-1817	2007
Uka K, Chayama K, at al	Similar effects of recombinant interferon-	Liver Int	27	1209-1216	2007

	alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma				
Tashiro H, Chayama K, at al	Complications after Duct-to-duct Biliary Reconstruction in Living-donor Liver Transplantation: Causes and Treatment	World J Surg	31	2222-2229	2007
Jeong SC, Chayama K, at al	Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma	World J Gastroenterol	13	5343-5350	2007
Jeong SC, Chayama K, at al	Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma	World J Gastroenterol	13	5188-5195	2007
Hiraga N, Chayama K, at al	The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration	J Gastroenterol	42	663-672	2007
Hatakeyama T, Chayama K, at al	Serum HBV-RNA is a Predictor of Early Emergence of YMDD Mutant in Patients Treated with Lamivudine	Hepatology	45	1179-1186	2007
Noguchi C, Chayama K, at al	Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol	J Gen Virol	88	432-440	2007
Uka K, Chayama K, at al	Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma	World J Gastroenterol	21	414-420	2007
Hiraga M, Chayama K, at al	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C	FEBS Letts	581	1983-1987	2007

	virus and its susceptibility to interferon				
Yatsuji H, Chayama K, at al	Successful treatment of an entecavir-resistant hepatitis B virus variant	J Med Virol	79	1811-1817	2007
Ohishi W, Chayama K, at al	Validation of the use of freeze-dried sera for the diagnosis of hepatitis B and C virus infections in a longitudinal study cohot	Res. Adv. In Microbiology	7	1-9	2007
Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, Yokoi T.	In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver.	Drug Metabolism and Disposition.	33	754 - 763	2005
Saito M, Kimoto M, Araki T, Shimada Y, Fujii R, Hide M, Usui T, Yoshizato K.	Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers.	Europian Urology.	48	865-871	2005
Nishimura M, Yokoi T, Tateno C, Kataoka M, Takahashi E, Horie T, Yoshizato K, Naito S.	Induction of human CYP1A1 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver.	Drug Metabol. Pharmacokin.	20	121-126	2005
Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Chayama K, Tateno C, Yoshizato K.	Infection of human hepatocyte chimeric mouse which genetically engineered hepatitis B virus.	Hepatology.	42	1046-1054	2005
Okumura K, Asahina K. Fujimori H, Ozeki R, Shimizu-Saito K, Tanaka Y, Teramoto K, Arii S, Takase Y, Kataoka M, Soeno Y, Tateno C, Yoshizato K, Teraoka H.	Generation of hybrid hepatocytes by cell fusion from monkey embryoid body cells in the injured mouse liver.	Histochemstry and Cell Biology.	125	247-257	2005
Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, Naito S, Tateno C, Yoshizato K, Yokoi T.	Expression of human phase II enzymes in chimeric mice with humanized liver.	Drug Metabolism and Disposition.	33	1333-1340	2005
Nishimura M, Yoshitugu H, Yokoi T,	Evaluation of mRNA expression of human drug-	Xenobiotica.	35	877-890	2005

Tateno C, Kataoka M, Horie T, Yoshizato K, Naito S.	metabolizing enzymes and transporters in Chimeric mouse with humanized liver.				
Emoto K, Tateno C, Hino H, Amano H, Imaoka Y, Asahina K, Asahara T, Yoshizato K.	Efficient In Vivo Xenogeneic Retroviral Vector-Mediated Gene Transduction into Human Hepatocytes.	HUMAN GENE THERAPY.	16	1138-1174	2005
Yamasaki C, Tateno C, Aratani A, Ohnishi C, Katayama S, Kohashi T, Hino H, Marusawa H, Asahara T, Yoshizato K.	Growth and differentiation of colony-forming human hepatocytes in vitro.	J. Hepatol.	44	749-757	2006
Aoki K, Kashiwagura Y, Horie T, Sato H, Tateno C, Ozawa N, Yoshizato K.	Characterization of Humanized Liver from Chimeric Mice Using Coumarin as a Human CYP2A6 and Mouse CYP2A5 Probe.	Drug Metab. Pharmacokin et.	21	277-285	2006
Yoshitsugu H, Nishimura M, Tateno C, Kataoka M, Takahashi E, Soeno Y, Yoshizato K, Yokoi T, Naito S.	Evaluation of Human CYP1A2 and CYP3A4 mRNA Expression in Hepatocytes from Chimeric Mice with Humanized Liver.	Drug Metab. Pharmacokin et.	21	465-474	2006
Hiraga N, Imamura M, Tsuge M, Noguchi C, Tanaka S, Iwao E, Fujimoto Y, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Sakai A, Sakai Y, Honda M, Kaneko S, Wakita T, Chayama K.	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon.	FEBS Letter.	581	1983-1987	2006
Gerashchenko B I, Yamagata A, Oofusa K, Yoshizato K, de Toledo S M, Howell R W.	Proteome analysis of proliferative response of bystander cells adjacent to cells exposed to ionizing radiation.	Proteomics.	7	2000-8	2007
Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, Yokoi T.	In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.	J Pharm Sci.	96	428-37	2007
Okumura H, Katoh M, Sawada T, Nakajima M,	Humanization of excretory pathway in chimeric mice	Toxicol Sci.	97	533 -8	2007

Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, Yokoi T.	with humanized liver.				
Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, Yokoi T, Yoshizato K, Suzuki H.	Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.	Hepatol Res.	37	548-56	2007
Masumoto N, Tateno C, Tachibana A, Utoh R, Morikawa Y, Shimada T, Momisako H, Itamoto T, Asahara T, Yoshizato K.	GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver.	J Endocrinol.	194	529-37	2007
Tokimitsu Y, Kishi H, Kondo S, Honda R, Tajiri K, Motoki K, Ozawa T, Kadowaki S, Obata T, Fujiki S, Tateno C, Takaishi H, Chayama K, Yoshizato K, Tamiya E, Sugiyama T, Muraguchi A.	Single lymphocyte analysis with a microwell array chip.	Cytometry Part A.	71A	1003 - 1010	2007
Utoh R, Tateno C, Yamasaki C, Hiraga N, Kataoka M, Shimada T, Cyayama K, Yoshizato K.	Susceptibility of Chimeric Mice with Livers Repopulated by Serially Subcultured Human Hepatocytes to Hepatitis B Virus.	Hepatplogy			in press.
吉里勝利	ヒト肝細胞キメラマウス.	化学と生物.	44	352-354	2006
大房　健、吉里勝利.	プロテオミクス研究とそれに注目した動機及びその後の発展について.	月刊細胞.	38	2-4	2006
吉里勝利.	キメラマウス.	医学のあゆみ.	218	805-807	2006
立野知世、森川良雄、吉里勝利.	ヒト肝細胞キメラマウス Chimric mice with human hepatocytes.	メディカルサイエンスダイジェスト.	33	650-651	2007
Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, Yokoi T.	In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.	J Pharm Sci.	96	428-37	2007
Okumura H, Katoh M, Sawada T, Nakajima M,	Humanization of excretory pathway in chimeric mice	Toxicol Sci.	97	533 -8	2007

Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, Yokoi T.	with humanized liver.				
Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, Yokoi T, Yoshizato K, Suzuki H.	Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.	Hepatol Res.	37	548-56	2007
Masumoto N, Tateno C, Tachibana A, Utoh R, Morikawa Y, Shimada T, Momisako H, Itamoto T, Asahara T, Yoshizato K.	GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver.	J Endocrinol.	194	529-37	2007
Tokimitsu Y, Kishi H, Kondo S, Honda R, Tajiri K, Motoki K, Ozawa T, Kadowaki S, Obata T, Fujiki S, Tateno C, Takaishi H, Chayama K, Yoshizato K, Tamiya E, Sugiyama T, Muraguchi A.	Single lymphocyte analysis with a microwell array chip.	Cytometry Part A.	71A	1003 - 1010	2007
Utoh R, Tateno C, Yamasaki C, Hiraga N, Kataoka M, Shimada T, Cyayama K, Yoshizato K.	Susceptibility of Chimeric Mice with Livers Repopulated by Serially Subcultured Human Hepatocytes to Hepatitis B Virus.	Hepatplogy			in press.
立野知世、森川良雄、吉里勝利.	ヒト肝細胞キメラマウス Chimric mice with human hepatocytes.	メディカルサイエンスダイジェスト.	33	650-651	2007
Takayuki Murata, Makoto Hijikata, Kunitada Shimotohno	Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059	Virology	340	105-115	2005
Hitoshi Takahashi, Masashi Yamaji, Masahiro Hosaka, Hiroe Kishine, Makoto Hijikata, Kunitada Shimotohno	Analysis of the 5' ent structure of HCV subgenomic RNA replicated in a Huh7 cell line	Intervirology	48(2-3)	104-111	2005
Koichi Watashi, Naoto Ishii, Makoto Hijikata, Daisuke	Cyclophilin B is functional regulator of Hepatitis C virus RNA	Mol. Cell.	19(1)	111-122	2005

Inoue, Takayuki Murata, Yusuke Miyanari, Kunitada Shimotohno	polymerase				
Takayuki Murata, Makoto Hijikiata, Kunitada Shimotohno	Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059	Virology	340	105-115	2005
Naoto Ishii, Koichi Watashi, Takayuki Hishiki, Kaku Goto, Daisuke Inoue, Makoto Hijikata, Takaji Wakita, Nobuyuki Kato, Kunitada Shimotohno	Diverse effects of cyclosporine on hepatitis C virus strain replication	J. Virol.	80	4510-4520	2006
Kaku Goto, Koichi Watashi, Takayuki Murata, Takayuki Hishiki, Makoto Hijikata, Kunitada Shimotohno	Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811	Biochem. Biophys. Res. Commun.	343	879-884	2006
Hussein H. Aly, Koichi Watashi, Makoto Hijikata, Hiroyasu Kaneko, Yasutugu Takada, Hiroto Egawa, Shinji Uemoto, Kunitada Shimotohno	Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes	J. Hepatol.	46	26-36	2007
Mohamed A. El-Farrash, Hussein H. Aly, Koichi Watashi, Makoto Hijikata, Hiroto Egawa, Kunitada Shimotohno	In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin	Microbiol. Immunol.	51(1)	127-133	2007
Yusuke Miyanari, Kimie Atsuzawa, Nobuteru Usuda, Koichi Watashi, Takayuki Hishiki, Margarita Zayas, Ralf Bartenschlager, Takaji Wakita, Makoto Hijikata, Kunitada Shimotohno	The lipid droplet is an important organelle for hepatitis C virus production.	Nat. Cell Biol.	9 (9)	1089-1097	2007

Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kaku Goto, Hussein H. Aly, Kunitada Shimotohno	Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptors with viral RNA polymerase NS5B	J. Biol. Chem.	282	32765-32772	2007
Chen CH, Nagayama K, Enomoto N, Miyasaka Y, Kurosaki M, Sakamoto N, Maekawa S, Kakinuma S, Ikeda T, Izumi N, Sato C, Watanabe M.	Enhancement of mitochondrial gene expression in the liver of primary biliary cirrhosis.	Hepatol Res	Jan;31 (1):	24-30	2005
Tanabe Y, Nagayama K, Enomoto N, Izumi N, Tazawa J, Kurosaki M, Sakamoto N, Sato C, Watanabe M.	Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy.	J Viral Hepat.	May;12 (3)	251-61	2005
Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsu Y, Takeda Y, Chen C-H, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M.	Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins	Gastroenterology	Sep;129(3)	1031-41	2005
Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M.	Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.	J Gastroenterol Hepatol	Sep;20 (9):	1401-9	2005
Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A.	Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.	Hepatology	Oct;42 (4):	962-73.	2005

Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N, Izumi N.	Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.	Intervirology	Nov-Dec;48 (6):	381-8.	2005
Asahina, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S.	Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C	J Hepatol	Oct;43 (4)	623-9	2005
Maekawa S, Enomoto N.	Genetic changes in the interferon sensitivity-determining region of hepatitis C virus (HCV) during the natural course of infection: an implication for the gene function in the role of chronic infection	J Gastroenterol	Jan;40 (1)	113-5	2005
Itakura J, Nagayama K, Enomoto N, Hamano K, Sakamoto N, Fanning LJ, Kenny-Walsh E, Shanahan F, Wanatabe	M. Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin	J Viral Hepatitis	Nov;12 (6):	594-603	2005
Yamashiro T, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Nakagawa M, Chen CH, Itsui Y, Koyama T, Takeda Y, Maekawa S, Enomoto N, Sakugawa H, Watanabe M.	Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3	J Gastroenterol	Aug;41 (8):	750-7	2006
Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, Takeda Y, Nakagawa M, Kakinuma S, Sekine Y, Maekawa S, Enomoto N, Watanabe M.	Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication	J Viral Hepat	Oct;13 (10):	690-700	2006

Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y, Chen CH, Kanazawa N, Nakagawa M, Kakinuma S, Yamashiro T, Itsui Y, Koyama T, Enomoto N, Watanabe M.	Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication	J Viral Hepat	Sep;13(9)	582-90	2006
Hosogaya S, Ozaki Y, Enomoto N, Akahane Y	Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C	Transl Res	Aug;148(2)	79-86	2006
Takano S, Kanai F, Jazag A, Ijichi H, Yao J, Ogawa H, Enomoto N, Omata M, Nakao A.	Smad4 is essential for downregulation of E-cadherin induced by TGF-{beta} in pancreatic cancer cell line PANC-1	J Biochem	Mar;141(3)	345-51	2007
Tasaka M, Sakamoto N, Itakura Y, Nakagawa M, Itusi Y, Sekine-Osajima Y, Nishimura-Sakurai Y, Chen CH, Yoneyama M, Fujita T, Wakita T, Maekawa S, Enomoto N, Watanabe M.	HCV nonstructural proteins responsible for suppression of RIG-I/Cardif -induced interferon response	J Gen Virol	Dec;88(Pt 12)	3323-33	2007
Sakamoto N, Tanabe Y, Yokota T, Satoh K, Sekine-Osajima Y, Nakagawa M, Itsui Y, Tasaka M, Sakurai Y, Cheng-Hsin C, Yano M, Ohkoshi S, Aoyagi Y, Maekawa S, Enomoto N, Kohara M,	Watanabe M. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA	J Gastroenterol Hepatol	[Epub ahead of print]		2007
Sekine-Osajima Y, Sakamoto N, Nakagawa N, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Wakita T, Enomoto N and Watanabe M.	Development of plaque assays for hepatitis C virus and isolation of mutants with enhanced cytopathogenicity and replication capacity	Virology	Feb 5;371(1):	71-85	2008
Amemiya F, Maekawa S, Itakura Y, Kanayama A, Matsui S, Takano S, Yamaguchi T, Itakura T, Kitamura	Targeting lipid metabolism in the treatment of hepatitis C	J Infect Dis	Feb 1;197(3)	361-70	2008

T, Inoue T, Sakamoto M, Yamauchi K, Okada S, Yamashita S, Sakamoto N, Itoh M, Enomoto N.					
Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y, Komatsu T, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Tasaka M, Sakamoto N, and Miyake S.	Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response	Gastroenterology	In press		2008
Jin H, Yamashita A, Maekawa S, Yang P, He L, Takayanagi S, Wakita T, Sakamoto N, Enomoto N, and Ito M.	Griseofulvin, an oral antifungal agent, suppresses HCV replication in vitro	Hepatol Res	in press		2008
Yoshinaga T Yasuda K Ogawa Y Nishikawa M Takakura Y	DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells	Immunology	120 (3)	295-302	2007
Kawano H Nishikawa M Mitsui M Takahashi Y Hattori K Yamaoka K Watanabe Y Takakura Y	Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA	Int. J. Cancer	121 (2)	401-6	2007
Takahashi Y Nishikawa M Takakura Y	Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1α expression in tumor cells and hepatocytes	Gene Ther.	In press		2008
Moriishi K., Mochizuki R., Moriya K., Miyamoto H., Mori Y., Abe T., Murata S., Tanaka K., Miyamura T., Suzuki T., Koike K., and Matsuura Y.	Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis	PNAS	104	1661-1666	2007

Abe T., Kaname Y., Hamamoto I., Tsuda Y., Wen X., Taguwa S., Moriishi K., Takeuchi O., Kawai T., Kanto T., Hayashi N., Akira S., and Matsuura Y	Hepatitis C Virus Nonstructural Protein 5A Modulates TLR-MyD88-Dependent Signaling Pathway in the Macrophage Cell Lines	J. Virol	81	8953-8966	2007
Mori Y., Yamashita T., Tanaka Y., Tsuda Y., Abe T., Moriishi K., and Matsuura Y	Processing of Capsid Protein by Cathepsin L Plays a Crucial Role in Replication of the Japanese Encephalitis Virus in Neural and Macrophage Cells	J. Virol	81	8477-8487	2007
Tani H., Komoda Y., Matsuo E., Suzuki K., Hamamoto I., Yamashita T., Moriishi K., Fujiyama K., Kanto T., Hayashi N., Owsianka A., Patel A.H., Whitt M.A., and Matsuura Y	Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins	J. Virol	81	8601-8612	2007
Yamamoto M., Uematsu S., Okamoto T., Matsuura Y., Sato S., Kumar H., Satoh T., Saitoh T., Takeda K., Ishii K.J., Takeuchi O., Kawai T., and Akira S.	Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency	J. Exp. Med.	204	2233-2239	2007
Moriishi K., and Matsuura Y	Host factors involved in the replication of hepatitis C virus	Rev. Med. Virol	17	343-354	2007
Miyamoto H., Moriishi K., Moriya K., Murata S., Tanaka K., Suzuki T., Miyamura T., Koike K., and Matsuura Y	Involvement of PA28γ-dependent pathway in insulin resistance induced by hepatitis C virus core protein	J. Virol	81	1727-1735	2007
Shirakura M., Murakami K., Ichimura T., Suzuki R., Shimoji T., Fukuda K., Abe K., Sato S., Fukasawa M., Yamakawa Y., Nishijima M.,	The E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein	J. Virol	81	1174-1185	2007

Moriishi K., Matsuura Y., Wakita T., Suzuki T., Howley P.M., Miyamura T., and Shoji I					
Nakai K., Okamoto T., Kimura-Someya T., Ishii K., Lim C-K.,Tani H., Matsuo E., Abe T., Mori Y., Suzuki T., Miyamura T., Nunberg J.H., Moriishi K., and Matsuura Y	Oligomerization of hepatitis C virus core protein is crucial for interaction with cytoplasmic domain of E1 envelope protein	J. Virol	80	80,11265-11273	2006
Okamoto T. Nishimura Y., Ichimura T., Suzuki K., Miyamura T., Suzuki T., Moriishi K., and Matsuura Y	Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90	EMBO J	25	5015-5025	2006
Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K. J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.-S., Sousa C. R., Matsuura Y., Fujita T., and Akira S	Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses	Nature	441	101-105	2006
Hamamoto I, Nishimura Y, Okamoto T, Aizaki H, Liu M, Mori Y, Abe T, Suzuki T, Lai MM, Miyamura T, Moriishi K, and Matsuura Y	Human VAP-B Is Involved in Hepatitis C Virus Replication through Interaction with NS5A and NS5B	J. Virol	79	13473-13482	2005
Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall H, Hammar L, Xing L, and Cheng RH.	Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus	J. Virol	79	12999-13006	2005
Abe T, Hemmi H, Moriishi K, Tamura S, Takaku H, Akira S, and Matsuura Y	Involvement of the toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus	J. Virol	79	2847-2858	2005

Kitagawa Y, Tani H, Limn CK, Matsunaga TM, Moriishi K, and Matsuura Y	Ligand-directed gene targeting to mammalian cells by pseudotype baculoviruses	J. Virol	79	3639-3652	2005
Mori Y, Okabayashi T, Yamashita T, Zhao Z, Wakita T, Yasui K, Hasebe F, Tadano M, Konishi E, Moriishi K, and Matsuura Y	Nuclear localization of Japanese encephalitis virus core protein enhances viral replication	J. Virol	79	3448-3458	2005
Suzuki R, Sakamoto S, Tsutsumi T, Rikimaru A, Tanaka K, Shimoike T, Moriishi K, Iwasaki T, Mizumoto K, Matsuura Y, Miyamura T, and Suzuki T	Molecular determinants for subcellular localization of hepatitis C virus core protein	J. Virol	79	1271-1281	2005
Honda M, Shimazaki T, Kaneko S.	La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation	Gastroenterology	128(2)	449-462	2005
Honda M, Kawai H, Shirota Y, Yamashita T, Kaneko S.	Differential gene expression profiles in stage I primary biliary cirrhosis	Am J Gastroenterol	100(9)	2019-2030	2005
Shimakami T, Honda M, Kusakawa T, Murata T, Shimotohno K, Kaneko S, Murakami S.	Effect of Hepatitis C Virus (HCV) NS5B-Nucleolin Interaction on HCV Replication with HCV Subgenomic Replicon	J Virol	80(7)	3332-3340	2006
Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, Nakamoto Y, Honda M, Wada T, Yokoyama H, Kaneko S.	Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study	Hepatol Res	36(3)	167-175	2006
Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S.	Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C	Hepatology	44(5)	1122-1138	2006

Sunagozaka H, Tsuji H, Mizukoshi E, Arai K, Kagaya T, Yamashita T, Sakai A, Nakamoto Y, Honda M, Kaneko S.	The development and clinical features of splenic aneurysm associated with liver cirrhosis	Liver Int	26(3)	291-297	2006
Tateno M, Honda M, Kawamura T, Honda H, Kaneko S.	Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy	J Infect Dis	195(2)	255-267	2007
Aburatani S, Sun F, Saito S, Honda M, Kaneko S, Horimoto K.	Gene systems network inferred from expression profiles in hepatocellular carcinogenesis by graphical Gaussian model	EURASIP J Bioinfo Systems Biol	47214	1-11	2007
Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S.	Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet	Hepatology	46(5)	1392-1403	2007
Oishi N, Shilagardi K, Nakamoto Y, Honda M, Kaneko S, Murakami S.	Hepatitis B virus X protein overcomes oncogenic RAS-induced senescence in human immortalized cells	Cancer Sci	98(10)	1540-1548	2007
Takamura T, Honda M, Sakai Y, Ando H, Shimizu A, Ota T, Sakurai M, Misu H, Kurita S, Matsuzawa-Nagata N, Uchikata M, Nakamura S, Matoba R, Tanino M, Matsubara K, Kaneko S.	Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes	Biochem Biophys Res Commun	361(2)	379-384	2007
Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S.	Impact of diabetes on recurrence of hepatocellular carcinoma	Am J Gastroenterol	102(9)	1939-1946	2007
Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, Iwao E, Fujimoto Y, Abe H,	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C	FEBS Lett	581(10)	1983-1987	2007

Maekawa T, Ochi H, Tateno C, Yoshizato K, Sakai A, Sakai Y, Honda M, Kaneko S, Wakita T, Chayama K.	virus and its susceptibility to interferon				
Tateno M, Honda M, Kawamura T, Honda H, Kaneko S.	Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy	J Infect Dis	195(2)	255-267	2007
Kaji K, Nakamoto Y, Kaneko S.	Analysis of hepatitis C virus-specific CD8+ T-cells with HLA-A*24 tetramers during phlebotomy and interferon therapy for chronic hepatitis C	Oncol Rep	18(4)	993-998	2007
Tachibana Y, Nakamoto Y, Mukaida N, Kaneko S	Intrahepatic interleukin-8 production during disease progression of chronic hepatitis C	Cancer Lett	251(1)	36-42	2007
Tsuchiyama T, Nakamoto Y, Sakai Y, Marukawa Y, Kitahara M, Mukaida N, Kaneko S	Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma	J Immunol	178(1)	574-583	2007
Minagawa H, Honda M, Miyazaki K, Tabuse Y, Teramoto R, Yamashita T, Nishino R, Takatori H, Ueda T, Kamijo K, Kaneko S.	Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma	Biochem Biophys Res Commun	366(1)	186-192	2008

Ⅲ. 研究成果の刊行物・別刷

（平成 17 年度）

G to A Hypermutation of Hepatitis B Virus

Chiemi Noguchi,[1,2] Hiromi Ishino,[1] Masataka Tsuge,[1] Yoshifumi Fujimoto,[3] Michio Imamura,[1,2] Shoichi Takahashi,[1,2] and Kazuaki Chayama[1,2,3]

G to A hypermutation of the human immunodeficiency virus type 1 (HIV-1) is induced by a deaminase APOBEC3G and is related to host antiviral defense. APOBEC3G has also been found to reduce the replication of HIV-1 by an unknown mechanism. This enzyme also reduces the production of hepatitis B virus, although the mechanism for this action has not been clearly elucidated. The hypermutated hepatitis B virus (HBV) is rarely found in usual sequencing analyses. Using peptide nucleic acid mediated by polymerase chain reaction clamping, we detected the hypermutated HBV DNA in 1 of 8 patients with acute HBV infection and 4 of 10 with chronic HBV infection. In the latter group, hypermutated genomes were found only in eAb-positive patients. As much as 72.5% of G residues were mutated in the hypermutated clones. G to A substitutions were predominant in almost all clones sequenced compared with other substitutions. G to A mutated viral genomes also were found in HepG2–derived cell lines that continuously produced HBV into the supernatant. Both alpha and gamma interferon reduced virus production in these cell lines, but they did not alter the frequency of the hypermutation. Transcripts of APOBEC3G, as well as some other deaminases, were found in these cell lines. In conclusion, our results show that part of the minus strand DNA of HBV is hypermutated both *in vitro* (HepG2 cell lines) and *in vivo*. The role and mechanism of hypermutation in reducing HBV replication should be further investigated to understand the anti-HBV defense system. (HEPATOLOGY 2005;41:626-633.)

Hepatitis B virus (HBV) is a small enveloped DNA virus that replicates in hepatocytes in a noncytolytic manner. Chronic infection with the virus often leads to chronic hepatitis and liver cirrhosis. Hepatocellular carcinoma arises in chronic carriers at a higher frequency than noninfected individuals.[1-4]

The replication cycle of the HBV includes pregenome RNA synthesis and reverse transcription, resulting in the production of the minus strand DNA, which serves as a template of the plus strand DNA.[5] The life cycle of this virus resembles that of the human immunodeficiency virus 1 (HIV-1), which also replicates through reverse transcription.[6]

Recent reports showed that a cytosine deaminase APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G), which is packaged in HIV-1 virions, induces G to A hypermutation to a nascent reverse transcript of HIV-1, which contributes in part to the innate antiviral activity.[7-10] The antiviral activity of APOBEC3G is species specific[11,12] and may represent the different actions of the protein.[13,14] The virion infectivity factor encoded by lentivirus genomes associates with APOBEC3G to prevent the enzyme from being packaged into virions and triggers its proteasomal degradation.[15-18] The negative strand DNA of the HBV might be a target of such antiviral deaminase activity. In fact, naturally occurring HBV genomes bearing the hallmarks of retroviral G to A hypermutation have been reported in clones obtained from 2 HBV carriers.[19] Both of these clones represented subgenomes arising from reverse transcrip-

Abbreviations: HBV, hepatitis B virus; HIV-1, human immunodeficiency virus type 1; APOBEC3G, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B early antigen; PCR, polymerase chain reaction; PNA, peptide nucleic acid.

From the [1]Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; [2]Hiroshima Liver Research Center, Hiroshima University, Hiroshima, Japan; and [3]Laboratory for Liver Diseases, SNP Research Center, Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan.

Received August 27, 2004; accepted December 2, 2004.

Supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Address reprint requests to: Kazuaki Chayama, M.D., Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. E-mail: chayama@hiroshima-u.ac.jp; fax: (81) 82-255-6220.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.20580

Conflict of interest: Nothing to report.

tion of packaged spliced mRNA. However, such hypermutated genomes have otherwise never been reported, nor deposited in DNA databases. Moreover, whether such hypermutated sequences are generated in liver cells or in leukocytes is unknown.

Inhibition of HBV replication by APOBEC3G was observed recently in a transient transfection system.[20] However, no induction of hypermutations to the HBV genome was observed. Instead, prevention of pre-genome RNA packaging was observed.

The aims of the current study were to determine the frequency of viral genomes with G to A substitutions in HBV carriers and patients with acute HBV infection, and to determine whether the hypermutated sequences are generated in hepatic cell lines. We identified such hypermutated viral genomes in 5 of 18 HBV carriers and patients with acute HBV infection and the expression of known deaminases that are potentially responsible for the hypermutation in cultured hepatoma cell lines.

Materials and Methods

Serum Samples. Serum samples from 18 adult Japanese patients with HBV infection were studied. At the time of the study, 8 of these patients had acute HBV infection and tested positive for immunoglobulin M anti–hepatitis B core antibody. The remaining 10 patients were chronic carriers. All serum samples were stored at −80°C until examined. All patients were negative for serum markers of both hepatitis C virus and HIV-1 infection, and none was on antiviral treatment.

Serological Markers of HBV Infection. Hepatitis B surface antigen (HBsAg) was detected by enzyme immunoassay (Roche Diagnostics, Basel, Switzerland), and hepatitis B early antigen (HBeAg) as well as anti-HBe were detected by radioimmunoassay (Abbott Diagnostics, Abbott Park, IL). HBV DNA was determined by transcription-mediated amplification and hybridization-protection assay (Chugai Diagnostics, Tokyo, Japan), and the results were expressed as log genome equivalents per milliliter. The lower detection limit of this assay is 3.7 log genome equivalents/mL (equivalent to 5,000 copies/mL). The antibody against hepatitis C virus was tested for by the third-generation enzyme immunoassay (Roche Diagnostics).

Analysis of HBV DNA in Cell Lines That Stably Produce HBV. Two cell lines known to produce wild-type HBV and one cell line known to produce lamivudine-resistant HBV (with mutations of L528M and M552V) were created by transfecting 1.4 genome length sequences of HBV to HepG2 cell lines. These cell lines produced HBV that showed a similar sedimentation in sucrose density gradient centrifugation to HBV extracted from the serum of carriers (M. Tsuge et al., manuscript in preparation) and could infect human hepatocyte chimeric mice (manuscript in preparation). These cell lines were grown in Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) fetal bovine serum at 37°C and 5% CO_2. Cells were seeded to semiconfluence in 6-well tissue culture plates and then treated with media containing interferon alpha or gamma. After 3 days of interferon treatment, the cells were harvested and lysed with 250 μL lysis buffer (10 mmol/L Tris-HCl [pH 7.4], 140 mmol/L NaCl, 0.5% [vol/vol] NP-40) followed by centrifugation for 2 minutes at 15,000*g*. Replicative intermediate of the HBV was immunoprecipitated and subjected to Southern blot analysis and quantitative analysis by light cycler. The effect of lamivudine was analyzed similarly, except that cells were harvested after 5 days of treatment.

Detection of Hypermutated Clones by Polymerase Chain Reaction With PNA Clamping, Cloning, and Sequencing. HBV DNA was extracted from 100 μL serum or culture supernatant by SMITEST (Genome Science Laboratories, Tokyo, Japan) and was dissolved in 20 μL H_2O. The first round of polymerase chain reaction (PCR) was performed with an outer primer set (PLF1 and BR112 [Table 1]) and a second-round PCR with an inner primer set (PLF2 and PLR2 [Table 1]). The peptic nucleic acid (PNA) oligonucleotide, initially designed to detect lamivudine-resistant variant genome,[21] was an 18-mer (PNA 552 [Table 1]) that exactly matched the 18-nucleotide sequence of the original YMDD sequence of DNA polymerase/reverse transcriptase, which contained GG and TG sequences (AGT TAT ATG GAT GAT GTG). The PCR with PNA clamping was performed in a total volume of 25 μL, consisting of a reaction buffer (100 mmol/L Tris-HCl [pH 8.3], 50 mmol/L KCl and 15 mmol/L $MgCl_2$), 0.2 mmol/L each of dNTPs, 1 μL of the DNA solution, 12.5 pmol each primer, 150 pmol PNA 552, and 1 unit of Taq DNA polymerase (Gene Taq, Wako Pure Chemicals, Tokyo, Japan) together with 0.2 μg anti-Taq high (Toyobo Co., Osaka, Japan). The amplification conditions included an initial denaturation at 95°C for 4 minutes and 25 cycles of amplification (denaturation at 95°C for 45 seconds, PNA annealing at 73°C for 2 minutes, annealing and extension of primer at 63°C for 50 seconds), followed by a final extension at 63°C for 7 minutes. Part of the X gene was amplified with an outer primer pair (HBV1 and HBV2) and an inner primer (PLF2 and HBV2) (Table 1) for the first- and second-round amplifications, respectively. The amplification for the first-round PCR included initial denaturation at 95°C for 4 minutes and 25 cycles of amplification (denatur-

Table 1. Oligonucleotides and PNAs Used in the Current Study

Primer	Sequence
	HBV amplification
PLF1	5′-GGT ATG TTG CCC GTT TGT CC-3′
BR112	5′-TTC CGT CGA CAT ATC CCA T-3′
PLF2	5′-CCT ATG GGA GTG GGC CTC AG-3′
PLR2	5′-CCA ATT ACA TAT CCC ATG AAG TTA AGG GA-3′
HBV1	5′-CCG GAA AGC TTG AGC TCT TCT TTT TCA CCT CTG CCT AAT CA-3′
HBV2	5′-CCG GAA AGC TTG AGC TCT TCA AAA AGT TGC ATG GTG CTG G-3′
BR109	5′-AAG GGA GTA GCC CCA ACG TT-3′
	PNA
PNA552	H2N-CAC ATC ATC CAT ATA ACT-CON2H
PNA552V	H2N-CAC ATC ATC CAC ATA ACT-CON2H
	Amplification of mRNAs of deaminases
APO1a	5′-CAG AGC ACC ATG ACT TCT-3′
APO1d	5′-ATT GTG GCC AGT GAG CTT CA-3′
APO2a	5′-AGA AGG AAG AGG CTG CTG TG-3′
APO2b	5′-AGA ACG GCT GCC TGC CAA CT-3′
APO2c	5′-GAA GGC TGG CAG GAT GGT GT-3′
APO2d	5′-CAG GTG ACA TTG TAC CGC AG-3′
APO3Aa	5′-TCT TAA CAC CAC GCC TTG AG-3′
APO3Ad	5′-GAA GAT GCG CAG TCT CAC GT-3′
APO3Ba	5′-AGA GCG GGA CAG GGA CAA GC-3′
APO3Bb	5′-GCG TAT CTA AGA GGC TGA AC-3′
APO3Bd	5′-CGA AGG ACC AAA GGG TCA TT-3′
APO3Be	5′-ACA AGT AGG TCT GGC GCC GT-3′
APO3Ca	5′-AGG ACG CTG TAA GCA GGA AG-3′
APO3Cb	5′-CCG ATG AAG GCA ATG TAT GG-3′
APO3Cc	5′-GTC GTC GCA GAA CCA AGA GA-3′
APO3Cd	5′-GAT GTG TAC CAG GTG ACC TG-3′
APO3Da	5′-CTG GGA CAA GCG TAT CTA AG-3′
APO3Dd	5′-AGT CTG AGA TGA AGA GGT GG-3′
APO3Fa	5′-CTT GGG TCC TGC CGC ACA GA-3′
APO3Fd	5′-TCA TCC TTG GCC GGC TAG TC-3′
APO3Ga	5′-GAC TAG CCG GCC AAG GAT GA-3′
APO3Gb	5′-CAC AGT GGA GCG AAT GTA TC-3′
APO3Gc	5′-GTT CGG AAT ACA CCT GGC CT-3′
APO3Gd	5′-ACT CCT GGT CAC GAT GCA GC-3′

ation at 95°C for 45 seconds, PNA annealing at 73°C for 2 minutes, primer annealing at 60°C for 1 minute, and extension of primer at 63°C for 4 minutes), followed by the final extension at 63°C for 7 minutes. The second-round amplification was performed under the same conditions without a primer extension for 3 minutes. The estimated error rate of the Taq DNA polymerase was 1.76×10^{-5} per site in amplifying approximately 10^2 copies of plasmid under the same conditions as described previously and cloning and sequencing.[21] Products (1 μL each) of the second-round of PNA PCR were subjected to PCR with primers PLF2 and BR109 for 35 cycles (94°C, 1 minute; 58°C, 1 minute; 72°C, 1.5 minutes) after initial denaturation at 94°C for 4 minutes and followed by the final extension at 72°C for 7 minutes. Amplicons were purified by electrophoresis on 2% (wt/vol) agarose gel and cloned into pGEM-T Easy Vector (Promega, Madison, WI) with the standard method, and then transformed into *Escherichia coli* JM 109 (Takara Shuzo Co., Otsu, Japan). Sequencing was performed in the ABI PLISMTM 310NT Genetic analyzer (Applied Biosystems, Tokyo, Japan) with Big Dye terminator version 3.0 Cycle Sequencing Ready Reaction kit (Applied Biosystems). Ten independent clones from each serum sample of patients or supernatant of cell cultures were sequenced for analysis and compared for nucleotide sequences obtained by direct sequencing of PCR products. Hypermutation was defined as clones with a statistically significant number of G to A substitutions.

Sequence Analysis. Nucleotide sequences were aligned and parameters of hypermutation were evaluated with Hypermut Program Package[22] (http://www.hiv.lanl.gov/HYPERMUT/hypermut.html). We used nucleotide sequences obtained by direct sequencing as reference sequences and tentatively labeled clones with a statistically significant ($P < .05$ by Fisher's exact test) number of G to A substitutions as "hypermutated."

Detection of mRNA of Known Deaminases by Reverse Transcription and PCR. Total RNA was extracted from HepG2 cell lines by using cell-to-cDNAII kit (Ambion, Austin, TX). The extracted RNA was reverse transcribed with random primer and M-MLV reverse transcriptase (ReverTra Ace, TOYOBO, Osaka, Japan) at 42°C for 60 minutes according to the instructions provided by the manufacturer. Synthesized cDNAs were used to detect mRNAs of known deaminases using primers listed in Table 1. Each of these primers was carefully designed to amplify only the target member of the APOBEC families. Amplification of specific deaminases was confirmed by amplifying each deaminase cDNA by using cDNAs obtained from organs reported to be positive for the expression of each deaminase. The amplicons were analyzed in 2% agarose gel, and the nucleotide sequences were confirmed by direct sequencing.

Results

Frequent Detection of G to A Substituted HBV Genomes by PCR With PNA Clamping in Patients With Acute or Chronic Hepatitis B Virus Infection. Using PCR with PNA clamping, clones with multiple G to A substitutions were found (Table 2). In contrast, only small numbers of other substitutions were identified in these clones. A hypermutated genome of HBV was found in 1 of 8 patients with acute HBV infection and 4 of 10 patients with chronic HBV infection (Table 2). We cloned and sequenced more than 20 clones without PNA and found no hypermutated clones. Among patients with chronic HBV infection, hypermutated clones were identified only in eAb-positive patients (Table 2). Figure 1